ILAISLAND PHARMACEUTICALS LIMITED
Announcement history available from 1 August 2025
Fromto
| Date / Time | Title | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 21 Aug 2026, 18:56 | Island boosts Galidesivir supply as Ebola surges | Company Update | MS | 11001 | |
| 13 Aug 2026, 19:21 | Date of AGM & Closing Date for Director Nominations | Meetings & Governance | — | 08006 | |
| 12 Aug 2026, 19:35 | Cleansing Notice | Securities Administration | — | 06018 | |
| 12 Aug 2026, 19:32 | Application for quotation of securities - ILA | Other | — | 06020 | |
| 7 Aug 2026, 18:43 | Investor presentation | Presentations | — | 03026 | |
| 30 July 2026, 19:47 | Quarterly Appendix 4C and Activities Report | Quarterly Reports | MS | 19004, 19009 | |
| 27 July 2026, 19:23 | Investor Presentation - TechKnow Invest Roadshow | Presentations | — | 03026 | |
| 14 July 2026, 02:29 | Notification regarding unquoted securities - ILA | Other | — | 06021 | |
| 14 July 2026, 02:27 | Notification regarding unquoted securities - ILA | Other | — | 06021 | |
| 14 July 2026, 02:21 | Notification regarding unquoted securities - ILA | Other | — | 06021 | |
| 14 July 2026, 02:21 | Notification regarding unquoted securities - ILA | Other | — | 06021 | |
| 13 July 2026, 19:46 | Texas Biomed SOW accelerates pivotal FDA pathway | Company Update | MS | 11001 | |
| 8 July 2026, 20:02 | Investor Presentation - Ebola Clinical Program | Presentations | MS | 03026 | |
| 8 July 2026, 19:00 | Notification of cessation of securities - ILA | Other | — | 06027 | |
| 7 July 2026, 19:02 | Galidesivir approved for treatment use in in Ebola epidemic | Company Update | MS | 09014, 11001, 14014 | |
| 3 July 2026, 22:23 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 3 July 2026, 22:01 | Pause in Trading | Trading Halt / Suspension | MS | 09005 | |
| 2 July 2026, 19:38 | Singapore Patent Expands Island's ISLA 101 Viral Protection | Company Update | MS | 11001 | |
| 17 June 2026, 18:54 | FDA Grants Orphan Designation for Galidesivir in Marburg | Company Update | MS | 11001 | |
| 16 June 2026, 19:58 | Investor Presentation - Asia Dengue Summit | Presentations | MS | 03026 | |
| 11 June 2026, 22:25 | Investor presentation (updated) | Presentations | — | 03026 | |
| 11 June 2026, 19:46 | Investor presentation | Presentations | MS | 03026, 14014 | |
| 10 June 2026, 18:53 | Island Secures USAMRIID Support for Galidesivir Study | Company Update | MS | 11001, 14014 | |
| 4 June 2026, 19:03 | Island Advances Galidesivir GMP Manufacturing for Biodefence | Company Update | MS | 11001 | |
| 21 May 2026, 19:25 | Island Adds Biodefence Leader as Filovirus Risks Escalate | Company Administration | MS | 12008 | |
| 19 May 2026, 18:44 | Island Bolsters US Biodefence Readiness Ahead of Trials | Company Update | MS | 11001 | |
| 28 Apr 2026, 18:30 | Cleansing Notice | Securities Administration | — | 06018 | |
| 28 Apr 2026, 18:23 | Application for quotation of securities - ILA | Other | — | 06020 | |
| 27 Apr 2026, 19:46 | Quarterly Appendix 4C and Activities Report | Quarterly Reports | MS | 19003, 19008 | |
| 30 Mar 2026, 22:19 | Cleansing Notice | Securities Administration | — | 06018 | |
| 30 Mar 2026, 22:17 | Application for quotation of securities - ILA | Other | — | 06020 | |
| 23 Mar 2026, 21:29 | Cleansing Notice | Securities Administration | — | 06018 | |
| 23 Mar 2026, 21:27 | Application for quotation of securities - ILA | Other | — | 06020 | |
| 9 Mar 2026, 20:47 | Antiviral pipeline expansion through strategic collaboration | Company Update | MS | 11001 | |
| 4 Mar 2026, 20:22 | US Government collaboration for Galidesivir development | Company Update | MS | 09014, 11001 | |
| 2 Mar 2026, 20:37 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 26 Feb 2026, 03:21 | Appendix 4D & Half-Year Financial Statements | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 16 Feb 2026, 19:28 | Cleansing Notice | Securities Administration | — | 06018 | |
| 16 Feb 2026, 19:21 | Application for quotation of securities - ILA | Other | — | 06020 | |
| 10 Feb 2026, 21:45 | Response to ASX Query Letter | ASX Query | MS | 17003 | |
| 5 Feb 2026, 20:57 | Investor presentation | Presentations | — | 03026 | |
| 4 Feb 2026, 20:34 | Proposed issue of securities - ILA | Securities Administration | — | 06013 | |
| 4 Feb 2026, 20:34 | $9m placement to advance US biodefence opportunity | Capital Raising | MS | 06003 | |
| 4 Feb 2026, 20:29 | FDA confirms Galidesivir approval pathway | Company Update | MS | 09014, 11001, 14014 | |
| 2 Feb 2026, 19:43 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 27 Jan 2026, 19:33 | Investor Presentation | Presentations | — | 03026 | |
| 27 Jan 2026, 19:32 | Quarterly Appendix 4C and Activities Report | Quarterly Reports | MS | 19002, 19007 | |
| 7 Jan 2026, 20:44 | US Patent Granted for Galidesivir in filoviridae viruses | Company Update | MS | 11001 | |
| 6 Jan 2026, 20:40 | Notification regarding unquoted securities - ILA | Other | — | 06021 | |
| 5 Jan 2026, 19:41 | Ongoing engagement with the US FDA | Company Update | MS | 11001 |
1–50 of 96
1 / 2